IQVIA Holdings Inc. reported a revenue increase of 5.9% for the fiscal year ending December 31, 2025, reaching $16.31 billion, compared to $15.41 billion in 2024. The growth was driven by a $380 million increase in the Technology & Analytics Solutions segment and a $298 million increase in the Research & Development Solutions segment. The company also noted a significant rise in cash flows from operating activities, totaling $2.65 billion, while net income attributable to IQVIA Holdings was $1.36 billion, slightly down from $1.37 billion in the previous year.
The company experienced a notable increase in costs, with the cost of revenues rising by 8.5% to $10.88 billion, primarily due to higher compensation and related expenses. Selling, general, and administrative expenses remained relatively stable at $1.99 billion. Additionally, IQVIA incurred $105 million in restructuring costs as part of ongoing efforts to streamline operations and integrate acquisitions. The company ended the year with total remaining performance obligations of approximately $34.2 billion, indicating a strong pipeline for future revenue.
Strategically, IQVIA has continued to expand its portfolio through acquisitions, investing $1.71 billion in net cash to acquire businesses across all three reportable segments. The company also announced a restructuring of its reportable segments, effective January 1, 2026, which will consolidate the Contract Sales & Medical Solutions segment into the Technology & Analytics Solutions segment, now renamed Commercial Solutions. This change aims to align with industry evolution and improve operational efficiency.
Operationally, IQVIA employed approximately 93,000 individuals across more than 100 countries, with a focus on enhancing its technology and analytics capabilities. The company reported a diversified client base of over 10,000 clients, with no single client accounting for more than 10% of total revenues. The company’s geographic revenue distribution showed that the Americas accounted for approximately 42% of total revenues, with significant contributions from Europe and Africa, and the Asia-Pacific region.
Looking ahead, IQVIA remains optimistic about its growth trajectory, driven by increasing demand for its services in the life sciences and healthcare sectors. The company anticipates continued revenue growth from its existing segments and plans to leverage its extensive data and analytics capabilities to enhance client offerings. However, management cautioned that ongoing macroeconomic factors and industry dynamics could impact client decision-making and spending in the near term.
About IQVIA HOLDINGS INC.
IQVIA is a global provider of healthcare data, analytics, and technology solutions serving the life sciences and healthcare industries. It offers clinical research services, real-world evidence, commercial insights, and AI-powered platforms to optimize drug development, clinical trials, and healthcare operations. With extensive proprietary data and a broad client base, IQVIA supports innovation, regulatory compliance, and improved patient outcomes worldwide.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.